Entyvio, Stelara plus immunomodulators not as effective for IBD


Sumary of Entyvio, Stelara plus immunomodulators not as effective for IBD:

  • “When used with an immunomodulator (ie, azathioprine, methotrexate), anti-TNFs are associated with lower rates of anti-drug antibodies and increased rates of clinical remission but also with increased rates of infections,”.
  • “[Entyvio (vedolizumab, Takeda)] and [Stelara (ustekinumab, Janssen)] are newer biologic therapies that do not seem to carry the same risk for infection as anti-TNFs or immunomodulators..
  • A growing body of evidence also suggests that these newer biologics have lower rates of immunogenicity and are not necessarily more effective when used with an immunomodulator..
  • Further prospective data are needed to determine efficacy and minimize risk for patients initiating combination therapy with vedolizumab or ustekinumab for IBD.”.
  • TARGET-IBD was a longitudinal cohort study of 4,229 patients with IBD, including those with ulcerative colitis and Crohn disease..
  • Lutz and colleagues collected data from electronic medical records for patients enrolled between July 2017 and November 2020..
  • Researchers estimated the rates of anti-TNF, vedolizumab and ustekinumab monotherapy and combination therapy with methotrexate, azathioprine or mercaptopurine from at any time during study and at time of enrollment..
  • Investigators stratified rates of combination therapy by time from drug approval and previous exposure to other biologic agents….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.